Clinical Trials Directory

Trials / Conditions / Thromboembolism

Thromboembolism

145 registered clinical trials studyying Thromboembolism12 currently recruiting.

StatusTrialSponsorPhase
RecruitingPreoperative Tranexamic Acid (TXA) to Prevent Bleeding in Patients Undergoing Major Colorectal Surgery
NCT06657924
Kristen BanPhase 2
Enrolling By InvitationEstimation of Cardiovascular Risk in Patients With Crohn's Disease and Ulcerative Colitis (PROVACI)
NCT07095634
IRCCS Policlinico S. Donato
RecruitingComparing Anticoagulation Strategies Using UFH, Argatroban and LMWH for ECMO Support
NCT06442267
Medical University of ViennaPhase 4
CompletedSYMPHONY-PE Study for Treatment of Pulmonary Embolism
NCT06062329
Imperative Care, Inc.N/A
CompletedECMO Hemostatic Transfusions in Children
NCT05796557
Yale UniversityPhase 4
CompletedLow Molecular Weight Heparin or no Treatment Following Cesarean Delivery
NCT06118957
University of UtahPhase 2
Enrolling By InvitationAntithrombin to Improve Thromboprophylaxis and Reduce the Incidence of Trauma-Related Venous Thromboembolism
NCT05794165
Bryan CottonPhase 2
Active Not RecruitingXueshuantong Injection (Lyophilized) in the Prevention of Venous Thromboembolism (VTE) in Hospitalized Patient
NCT06443905
China-Japan Friendship Hospital
RecruitingIn Vivo Detection of Circulating Clots in Patients With Thromboembolism
NCT05301348
University of ArkansasN/A
CompletedTINzaparin Prophylaxis in Patients With Metastatic Colorectal Cancer
NCT05625932
Galician Research Group on Digestive TumorsPhase 3
RecruitingOptimization of Management in Patients With Cardiovascular Disease After Lower Limb Joint Replacement
NCT06627933
I.M. Sechenov First Moscow State Medical University
CompletedVenous Thromboembolism (VTE) Knowledge
NCT05548010
Chinese University of Hong Kong
CompletedThromboembolism in Anorexia Nervosa
NCT05575466
Odense University Hospital
Active Not RecruitingAtrial Fibrillation and Cancer: a Nationwide French Cohort Study
NCT05563883
University Hospital, Caen
CompletedA Study to Compare Health Care Costs Between Apixaban and Low Molecular Weight Heparin in Patients With Venous
NCT05643885
Pfizer
CompletedStrategies for Anticoagulation During Venovenous ECMO
NCT04997265
Vanderbilt University Medical CenterN/A
RecruitingEffect of Tofacitinib on Coagulation and Platelet Function, and Its Role in Thromboembolic Events
NCT05313620
Fundación de Investigación Biomédica - Hospital Universitario de La PrincesaPhase 4
RecruitingLong-term Anticoagulation With Oral Factor Xa Inhibitor Versus Vitamin K Antagonist After Mechanical Aortic Va
NCT04258488
Joon Bum KimPhase 4
UnknownThe Impact of Thromboprophylaxis on Progression Free Survival of Patients With Advanced Pancreatic Cancer
NCT05178628
Michalis KaramouzisPhase 3
UnknownThe Influencing Factors and Mechanism of High Incidence of Thrombotic Events in Patients With MN and DKD
NCT05656963
Yipeng Liu
UnknownCOVID-19 Pathophysiology of Long Term Implications
NCT04813575
King Faisal Specialist Hospital & Research CenterN/A
RecruitingThe Frequency of Peripheral Arterial Disease in Patients with Deep Vein Thrombosis of the Lower Limbs
NCT06806540
IRCCS Azienda Ospedaliero-Universitaria di Bologna
UnknownThromboprophylaxis in Oesophageal Cancer Patients
NCT05067153
University of AarhusPhase 4
UnknownCellular-Mediated Immunity in COVID-19
NCT04746521
University of Campania Luigi Vanvitelli
RecruitingPregnancy and Risk of Venous Thromboembolism
NCT03659708
Hospices Civils de LyonN/A
CompletedEndovascular thromBectomy of Acute Mesentery Vessels Occlusion Hybrid With Emergent Laparoscopic Surgery
NCT04686981
Beijing Tsinghua Chang Gung Hospital
CompletedPractice of Adjunctive Treatments in Intensive Care Unit Patients With COVID-19
NCT04719182
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
TerminatedLavare Cycle in Patients Receiving HeartWare Left Ventricular Assist Device
NCT04199793
Vanderbilt University Medical CenterN/A
CompletedThromboembolic Risk Screening in Patients With Cancer and COVID-19
NCT04616846
Centre Antoine LacassagneN/A
CompletedImpact of Prophylactic Low-molecular Weight Heparin Dosing on Clotting Parameters Following Cesarean Delivery
NCT04305756
University of UtahN/A
CompletedImpact of an Intensified Thromboprofylaxis Protocol in COVID-19
NCT04394000
Jessa Hospital
CompletedIs Anti-Factor Xa Associated With Outcome in Patients With Critical COVID-19 on Low-Molecular-Weight Heparin?
NCT05256524
Karolinska Institutet
CompletedDosing of Thromboprophylaxis and Mortality in Critically Ill COVID-19 Patients
NCT04593654
Karolinska Institutet
CompletedInfluence of Cardiac Implantable Electronic Devices on the Hemostatic System
NCT04499612
Ryazan State Medical University
UnknownBiomarkers of Thrombosis as Predictors of Venous Thromboembolism Risk in Cancer Patients
NCT04301362
Centro Hospitalar de Vila Nova de Gaia/Espinho, E.P.E.
CompletedApixaban in Adults With Congenital Heart Disease and Atrial Arrhythmias: the PROTECT-AR Study
NCT03854149
AHEPA University Hospital
CompletedStudy on Impact of Edoxaban Treatment in Cancer Patients With Venous Thromboembolism During Antineoplastic The
NCT04072068
Gruppo Oncologico Italiano di Ricerca ClinicaPhase 4
UnknownBiomarkers of Acute Stroke in Clinic
NCT03897478
Ischemia Care LLC
UnknownCoagulation System In STereotactic Radiotherapy Of NSCLC
NCT03893461
Odense University Hospital
UnknownExploring Cancer-Associated Thromboembolism Prognosis Biomarkers and Polymorphisms
NCT06065592
Lebanese UniversityPhase 1
UnknownProspective Evaluation of Efficacy and Safety of Fondaparinux in Surgical Cancer Patients, Risk Factors for Th
NCT04246073
Hellenic Society of Surgical Oncology
Active Not RecruitingPeripheral Systemic Thrombolysis Versus Catheter Directed Thrombolysis for Submassive PE
NCT03581877
Northwell HealthPhase 4
UnknownEvaluation of ReX-C System in Measurement and Improvement of Patients' Adherence.
NCT03424330
Dosentrx Ltd.N/A
CompletedPraxbindTM India PMS Program
NCT03359889
Boehringer Ingelheim
RecruitingRegistry of Thrombosis & NEoplasia of "Sociedad Española de Oncología Médica"
NCT03855592
Fundación Sociedad Española de Oncologia Médica
UnknownTecarfarin Anti-Coagulation Trial (TACT)
NCT02522221
Espero BiopharmaPhase 3
WithdrawnAbsorption of Rivaroxaban in Patients With Cervical Spinal Cord Injury
NCT02970773
Swiss Paraplegic Research, NottwilPhase 4
CompletedDVT After Cardiac Procedure
NCT03877770
Manchester University NHS Foundation Trust
CompletedBalancing of Patients Treated by Vitamin K Antagonists (VKAS) in General Medicine
NCT03914053
University Hospital, Montpellier
CompletedA Clinical Trial Comparing Efficacy and Safety of Dabigatran Etexilate With Warfarin in Patients With Cerebral
NCT02913326
Boehringer IngelheimPhase 3
CompletedAMPLATZER™ LAA Occluder Post Approval Study (PAS)
NCT02964208
Abbott Medical Devices
CompletedInflammatory Bowel Disease and Thromboembolic Events
NCT05162339
Centro Hospitalar Tondela-Viseu
CompletedApixaban Discontinuation Prior to Major Surgery
NCT02935751
Thomas Jefferson University
CompletedSafety, Pharmacokinetics, Biodistribution, and Diagnostic Performance of [18F]GP1 PET in Thromboembolism
NCT02864810
Asan FoundationPhase 1
CompletedAssessment of a Diagnostic Medical Device for the INR (International Normalized Ratio) Measurement
NCT02779400
University Hospital, GrenobleN/A
CompletedPatient-Centered Anticoagulation Self-Monitoring in Minority Patients
NCT02776566
University of Illinois at ChicagoN/A
CompletedRivaroxaban for Treatment in Venous or Arterial Thrombosis in Neonates
NCT02564718
BayerPhase 1 / Phase 2
TerminatedREVIparin-BRIDging-in a General Practice Setting in GErmany
NCT02579122
Mylan Inc.
TerminatedObservational Study of Thrombogenic Properties in 220 Patients With Proximal Femur Fracture
NCT02475187
Vestre Viken Hospital Trust
RecruitingLAAC-registry: Clinical Outcome After Echocardiography-guided LAA-closure
NCT04628078
Insel Gruppe AG, University Hospital Bern
CompletedAmplatzer™Amulet™ Post-Market Study (Amulet™PMS)
NCT02447081
Abbott Medical Devices
CompletedThe Effect of Medication Timing on Anticoagulation Stability in Users of Warfarin: The "INRange" RCT
NCT02376803
University of AlbertaPhase 4
UnknownInvestigation on Appropriate Duration of Dabigatran Use After Catheter Ablation for Paroxysmal Atrial Fibrilla
NCT02313584
Korea UniversityPhase 3
CompletedInfluence of ABCB1 Polymorphisms on Plasma Concentrations of New Oral Anticoagulants in Case of Serious Advers
NCT02103101
Centre Hospitalier Universitaire de BesanconN/A
CompletedReduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE(Venous Thromboembolism)
NCT02064439
BayerPhase 3
UnknownEvaluation of the Risk of VTE Among Patients Hospitalized in Non-surgical Departments
NCT03073915
Hadassah Medical Organization
UnknownProphylaxis of Venous Thromboembolism After Bariatric Surgery
NCT02295150
Rijnstate HospitalPhase 4
CompletedStudy to Evaluate a Single Dose of Apixaban in Pediatric Participants at Risk for a Thrombotic Disorder
NCT01707394
Bristol-Myers SquibbPhase 1
CompletedEvaluation of Contrast Medium Enhanced Post-mortem CT in Virtual Autopsy
NCT01541995
Universitätsklinikum Hamburg-Eppendorf
CompletedFiix-prothrombin Time for Monitoring Warfarin
NCT01565239
Landspitali University HospitalPhase 2
CompletedRivaroxaban in Endovenous Laser Ablation With and Without Miniphlebectomy
NCT02584842
University Hospital, Basel, Switzerland
TerminatedFollow on Study From RE-ALIGN
NCT01505881
Boehringer IngelheimPhase 2
CompletedGenetics Informatics Trial (GIFT) of Warfarin to Prevent DVT
NCT01006733
Washington University School of MedicinePhase 3
CompletedAspirin and Compression Devices for VTE Prophylaxis in Orthopaedic Oncology
NCT01696760
Ohio State University Comprehensive Cancer CenterN/A
UnknownSubclinical Atherosclerosis Using Dual-source CT Coronary Angiography in Chinese Adults With Different Glycaem
NCT01319201
Shanghai Jiao Tong University School of Medicine
CompletedSwitching Drug Therapy for the Prevention of Blood Clot Formation From Enoxaparin to Rivaroxaban After Orthope
NCT01094886
Ortho-McNeil Janssen Scientific Affairs, LLCPhase 3
CompletedRetrospective Study of Patients Who Were Treated With Fondaparinux Pre-, Peri- and/or Postpartum for Prophylax
NCT01004939
GlaxoSmithKline
CompletedRole of Coumadin in Preventing Thromboembolism in Atrial Fibrillation (AF) Patients Undergoing Catheter Ablati
NCT01006876
Texas Cardiac Arrhythmia Research FoundationPhase 3
CompletedComparative Investigation of Low Molecular Weight (LMW) Heparin/Edoxaban Tosylate (DU176b) Versus (LMW) Hepari
NCT00986154
Daiichi SankyoPhase 3
UnknownThromboembolic Complications Related to Asparaginase in Children With Acute Lymphoblastic Leukemia (ALL) Treat
NCT00982514
Oslo University Hospital
CompletedDose Adjusting Enoxaparin Thromboprophylaxis Dosage According to Anti-factor Xa Plasma Levels Improve Pregnanc
NCT01068795
HaEmek Medical Center, IsraelN/A
CompletedPradaxa (Dabigatran Etexilate) 150 mg/q.d. in Patients With Moderate Renal Impairment After Hip or Knee Replac
NCT00847301
Boehringer Ingelheim
WithdrawnA Cohort Study With 100 Subjects Having a Primary Total Knee Replacement, Taking Pradax Post Discharge for Ten
NCT00868179
Ross LeightonPhase 4
CompletedStandard Diagnostic Procedures With or Without Fludeoxyglucose F 18 Positron Emission Tomography in Finding Ca
NCT00964275
University Hospital, BrestN/A
CompletedPradaxa (Dabigatran Etexilate 220 mg/q.d. in the General Population After Hip or Knee Replacement Surgery
NCT00846807
Boehringer Ingelheim
TerminatedStudy to Evaluate the Safety and Efficacy of Pradaxar for the Prevention of Venous Thromboembolism in the Mexi
NCT00967447
Boehringer Ingelheim
CompletedBiomarkers Related to Thrombosis in Patients With Newly Diagnosed Multiple Myeloma Receiving Chemotherapy
NCT01132833
UNC Lineberger Comprehensive Cancer Center
CompletedSALTO - Epidemiological Study on Compliance and Treatment Satisfaction
NCT00911001
Bayer
CompletedApplying Pharmacogenetic Algorithms to Individualize Dosing of Warfarin
NCT00927862
Intermountain Health Care, Inc.Phase 2 / Phase 3
CompletedA Phase 2b Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Total Hip Arthroplasty
NCT01203098
Daiichi Sankyo Co., Ltd.Phase 2
CompletedPhase III Study Testing Efficacy & Safety of Oral Dabigatran Etexilate vs Warfarin for 6 m Treatment for Acute
NCT00680186
Boehringer IngelheimPhase 3
TerminatedTapered Warfarin or Interrupted Warfarin With Heparin Bridging for Pacemaker or Defibrillator Implantation
NCT02094157
McMaster UniversityPhase 3
TerminatedChemotherapy With or Without Dalteparin in Treating Patients With Metastatic Pancreatic Cancer
NCT00662688
GERCOR - Multidisciplinary Oncology Cooperative GroupPhase 3
CompletedSpecial Drug Use Investigation for ARIXTRA® (Fondaparinux) Injection
NCT01420809
GlaxoSmithKline
UnknownDalteparin in Preventing Blood Clots in Patients With Lung Cancer
NCT00519805
Velindre NHS TrustPhase 3
CompletedThe Clinical and Economic Impact of Pharmacogenomic Testing of Warfarin Therapy in Typical Community Practice
NCT00830570
Medco Health Solutions, Inc.
CompletedA Study to Assess the Safety of a Potential New Drug in Comparison to the Standard Practice of Dosing With War
NCT00504556
Daiichi SankyoPhase 2
CompletedSelf-management of Low Molecular Weight Heparin Therapy
NCT00794560
University Hospital, Basel, SwitzerlandPhase 4
CompletedImpact of Left Atrial Appendage Exclusion on Short-Term Clinical Outcomes and Long-Term Stroke Incidence
NCT00486915
London Health Sciences CentreN/A
TerminatedAnticoagulation and Inferior Vena Cava Filters in Cancer Patients With a Venous Thromboembolism
NCT00423683
Northwell HealthPhase 3
CompletedFondaparinux in Preventing Blood Clots in Patients Undergoing Surgery for Gynecologic Cancer
NCT00381888
Masonic Cancer Center, University of MinnesotaPhase 2
CompletedA Comparison of Certoparin and Unfractionated Heparin in the Prevention of Thromboembolic Events in Acutely Il
NCT00451412
NovartisPhase 3
CompletedFactor Xa Inhibitor for Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Knee Replac
NCT00408239
Astellas Pharma IncPhase 2
CompletedIncidence of Blood Clots in Patients Undergoing Chemotherapy for Solid Tumors
NCT00433602
European Organisation for Research and Treatment of Cancer - EORTC
UnknownThromboprophylaxis and Bariatric Surgery
NCT00444652
University Hospital, Strasbourg, FrancePhase 4
UnknownInstitutional Registry of Thromboembolic Disease
NCT01372514
Hospital Italiano de Buenos Aires
CompletedAspirin and Statins for Prevention of Atherosclerosis and Arterial Thromboembolism in Systemic Lupus Erythemat
NCT00371501
Tuen Mun HospitalPhase 4
CompletedFactor Xa Inhibitor YM150 for the Prevention of Blood Clot Formation in Veins After Scheduled Hip Replacement
NCT00353678
Astellas Pharma IncPhase 2
CompletedFactor Xa Inhibitor, PRT054021, Against Enoxaparin for the Prevention of Venous Thromboembolic Events (EXPERT)
NCT00375609
Portola PharmaceuticalsPhase 2
CompletedSecondary Prevention of Venous Thrombo Embolism (VTE).
NCT00329238
Boehringer IngelheimPhase 3
CompletedHip Fracture Study of GSK576428 (Fondaparinux Sodium)
NCT00320424
GlaxoSmithKlinePhase 3
CompletedEfficacy and Safety of Dabigatran Compared to Warfarin for 6 Month Treatment of Acute Symptomatic Venous Throm
NCT00291330
Boehringer IngelheimPhase 3
CompletedHTRS TE Registry (ThromboEmbolism Registry)
NCT00266994
Nationwide Children's Hospital
TerminatedMelagatran/Ximelagatran Versus Enoxaparin for the Prevention of Venous Thromboembolic Events
NCT00206089
AstraZenecaPhase 3
CompletedAnticoagulant After Implantation of Biological Aortic Valve Comparing With Aspirin
NCT01452568
Rigshospitalet, DenmarkPhase 4
CompletedRisk Factors for Developing a Blood Clot in Patients Who Are Undergoing Cancer Treatment for Newly Diagnosed G
NCT00253669
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
CompletedDetecting Abnormal Blood Clotting in Patients With Metastatic Cancer Undergoing Surgery
NCT00096590
National Cancer Institute (NCI)
CompletedDabigatran Etexilate vs Enoxaparin in Prevention of Venous Thromboembolism (VTE) Post Total Knee Replacement
NCT00152971
Boehringer IngelheimPhase 3
CompletedRE-MODEL Dabigatran Etexilate 150mg or 220mg Once Daily (o.d.) Versus (v.s.) Enoxaparin 40mg o.d. for Preventi
NCT00168805
Boehringer IngelheimPhase 3
CompletedDabigatran Etexilate in Extended Venous Thromboembolism (VTE) Prevention After Hip Replacement Surgery
NCT00168818
Boehringer IngelheimPhase 3
CompletedSafety Study of Stopping Thromboprophylaxis Based on Ultrasound Results After Total Knee Replacement
NCT00362492
University Hospital, CaenPhase 4
CompletedARIXTRA Local Study For Registration In China.
NCT00328939
GlaxoSmithKlinePhase 3
CompletedClotting Genetic Variants, Hormones, and Venous Thrombosis
NCT00094185
University of Washington
CompletedA Comparison of Dalteparin and Tinzaparin for Prevention of Blood Clots in Hemodialysis Patients on Oral Antic
NCT00260988
Ottawa Hospital Research InstitutePhase 2 / Phase 3
CompletedOASIS-6 : The Safety and Efficacy of Fondaparinux Versus Control Therapy in Patients With ST Segment Elevation
NCT00064428
GlaxoSmithKlinePhase 3
CompletedSafety and Effectiveness of Two Blood Transfusion Strategies in Surgical Patients With Cardiovascular Disease
NCT00071032
Rutgers, The State University of New JerseyPhase 3
CompletedMichelangelo - Oasis 5
NCT00139815
GlaxoSmithKlinePhase 3
TerminatedProphylaxis In Venous Thromboembolism In Primary Care, A Pilot Study
NCT00655122
PfizerPhase 4
CompletedGemcitabine With or Without Dalteparin in Treating Patients With Locally Advanced or Metastatic Pancreatic Can
NCT00462852
Hull University Teaching Hospitals NHS TrustPhase 2
CompletedODiXahip - a Phase IIa Dose Escalating Proof of Principle Trial
NCT00839826
BayerPhase 2
TerminatedGemcitabine With or Without Dalteparin in Treating Patients With Unresectable or Metastatic Pancreatic Cancer
NCT00031837
Gary MorrowPhase 3
CompletedEpidemiology of Venous Thromboembolism
NCT00041457
Brigham and Women's Hospital
Completed12-h and 2-h Urokinase Regimes of Pulmonary Thromboembolism in China
NCT00799968
Beijing Chao Yang HospitalPhase 4
CompletedLow Dosage of rt-PA in the Treatment of Pulmonary Thromboembolism in China
NCT00781378
Beijing Chao Yang HospitalPhase 4
CompletedNadroparin for the Initial Treatment of Pulmonary Thromboembolism
NCT00796692
Beijing Chao Yang HospitalPhase 4
CompletedA Study to Evaluate the Efficacy and Safety of Fondaparinux Sodium When Used With Intermittent Pneumatic Compr
NCT00038961
GlaxoSmithKlinePhase 3
CompletedRisk Factors for Venous Thromboembolism in the Community
NCT00011180
Mayo Clinic
CompletedCombination Chemotherapy Plus Warfarin in Treating Patients With Prostate Cancer
NCT00014352
Memorial Sloan Kettering Cancer CenterPhase 2
CompletedFlavopiridol in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
NCT00020189
National Cancer Institute (NCI)Phase 2
CompletedWarfarin in Preventing Blood Clots in Cancer Patients With Central Venous Catheters
NCT00024297
Cancer Research Campaign Clinical Trials CentreN/A
CompletedComparison of Patient Outcomes Using Different Delivery Models of Anticoagulation Care
NCT00205400
University of Wisconsin, MadisonN/A
CompletedPrevention of Recurrent Venous Thromboembolism (PREVENT)
NCT00000614
National Heart, Lung, and Blood Institute (NHLBI)Phase 3
CompletedAssessment of Long-Term Out-of-Hospital Treatment of Patients With Proximal Deep Vein Thrombosis (DVT) Using L
NCT00203658
University of CalgaryPhase 4
CompletedHeparin or Enoxaparin in Patients With Cancer
NCT00004875
Northwestern University
CompletedTrial of the Effect of Low-Molecular-Weight Heparin (LMWH) Versus Warfarin on Mortality in the Long-Term Treat
NCT00203580
University of CalgaryPhase 4